-
1.发明授权公开(公告)号：US09044478B2
公开(公告)日：2015-06-02
申请号：US11666220
申请日：2005-11-08
申请人： Nicolas Sergeant , Andre Delacourte , Patricia Melnyk , Luc Buee
发明人： Nicolas Sergeant , Andre Delacourte , Patricia Melnyk , Luc Buee
IPC分类号： A61K31/495 , C07D215/12 , C07D219/08 , C07D219/12 , C07D235/30 , C07D239/26 , C07D277/28 , C07D295/027 , C07D295/13 , C07D403/12
CPC分类号： A61K31/495 , C07D215/12 , C07D219/08 , C07D219/12 , C07D235/30 , C07D239/26 , C07D277/28 , C07D295/027 , C07D295/13 , C07D403/12
摘要： Use of 1,4-bis(3-aminoalkyl)piperazine derivatives as defined in formula I or II for the manufacture of a pharmaceutical composition intended for the treatment of neurodegenerative diseases, related neurodegenerative diseases, developmental diseases or cancer. The instant invention is also directed to some specific 1,4-bis(3-aminoalkyl)piperazine derivatives and pharmaceutical composition including them.
-
2.发明授权Antibodies specific of the β-amyloid peptides and their uses as diagnostic agents or drugs 失效β-淀粉状蛋白肽特异性抗体及其用途作为诊断剂或药物公开(公告)号：US08343493B2
公开(公告)日：2013-01-01
申请号：US12740217
申请日：2008-10-24
申请人： Eugeen VanMechelen , Pierre Grognet , Nicolas Sergeant , Marie Gompel , Andre Delacourte , Luc Buee , Laurent Pradier , Veronique Blanchard-Bregeon
发明人： Eugeen VanMechelen , Pierre Grognet , Nicolas Sergeant , Marie Gompel , Andre Delacourte , Luc Buee , Laurent Pradier , Veronique Blanchard-Bregeon
IPC分类号： A61K39/395 , C12P21/08 , C07K16/18 , C12N5/20 , C12N5/12 , G01N33/533 , G01N33/534 , G01N33/535
CPC分类号： C07K16/18 , A61K2039/505 , C07K14/4711 , C07K2317/56 , C07K2317/565 , C07K2317/92
摘要： A monoclonal antibody which specifically binds to the N-terminal region of Aβ8-x peptide, x being included from 11 to 42, and recognizes neither Aβ1-40 nor Aβ1-42 and which presents a high affinity with respect to Aβ8-x peptide, such as determined by an immunological complex formation between the monoclonal antibody and the peptide Aβ8-x.
摘要翻译： 特异性结合A＆Bgr。8-x肽的N-末端区域的单克隆抗体，x包含在11至42中，并且既不识别A＆bgr; 1-40也不识别为1-42，并且与 至A-Bgr; 8-x肽，例如通过单克隆抗体和肽A和Bgr之间的免疫复合物形成确定8-x。
-
3.发明申请ANTIBODIES SPECIFIC OF THE BETA-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC AGENTS OR DRUGS 失效抗坏血酸蛋白酶的抗体及其作为诊断试剂或药物的用途公开(公告)号：US20110059092A1
公开(公告)日：2011-03-10
申请号：US12740217
申请日：2008-10-24
申请人： Eugeen Vanmechelen , Pierre Grognet , Nicolas Sergeant , Marie Gompel , Andre Delacourte , Luc Buee , Laurent Pradier , Veronique Blanchard-bregeon
发明人： Eugeen Vanmechelen , Pierre Grognet , Nicolas Sergeant , Marie Gompel , Andre Delacourte , Luc Buee , Laurent Pradier , Veronique Blanchard-bregeon
IPC分类号： A61K39/395 , A61K39/00 , G01N33/53 , C12N9/96 , C12N5/16 , G01N33/566 , C07K7/00 , C07K16/18 , A61P25/28
CPC分类号： C07K16/18 , A61K2039/505 , C07K14/4711 , C07K2317/56 , C07K2317/565 , C07K2317/92
摘要： The present invention relates to a monoclonal antibody which specifically binds to the N-terminal region of Aβ8-x peptide, x being comprised from 11 to 42, and recognises neither Aβ1-40 nor Aβ1-42 and which presents a high affinity with respect to Aβ8-x peptide, such as determined by an immunological complex formation between the monoclonal antibody and the peptide Aβ8-x.
摘要翻译： 本发明涉及特异性结合A-Bgr-8-x肽的N-末端区域的单克隆抗体，x由11至42组成，并且不识别A和Bgr 1-40和A＆bgr 1-42，其中 相对于A＆Bgr; 8-x肽的高亲和力，例如通过单克隆抗体和肽A和Bgr之间的免疫复合物形成8-x来确定。
-
4.发明申请Means for detecting pathological transformation of the app protein and their uses 有权用于检测应用蛋白质病理转化及其用途的方法公开(公告)号：US20070026527A1
公开(公告)日：2007-02-01
申请号：US10415479
申请日：2001-11-05
IPC分类号： G01N33/50
CPC分类号： G01N33/6896 , G01N2500/00 , G01N2800/2821
摘要： A method of intra-articular drug delivery may include selecting an attachment zone in a synovial joint; affixing a drug release device in the attachment zone, the drug release device comprising a base affixable in the attachment zone, a sustained-release drug carrier, and a drug, the device positioned so that the device releases the drug into the synovial fluid of the synovial joint, and so that agitation of the synovial fluid facilitates elution of the drug from the drug release device.
摘要翻译： 关节内药物递送的方法可包括选择滑膜关节中的附着区域; 将药物释放装置固定在附着区域中，所述药物释放装置包括可固定在附着区域中的基底，缓释药物载体和药物，所述装置被定位成使得所述装置将药物释放到所述粘液的滑液中 滑液关节，并且使得滑液的搅动促进药物从药物释放装置的洗脱。
-
5.发明申请Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases 有权使用1,4-双（3-氨基烷基）哌嗪衍生物治疗神经变性疾病公开(公告)号：US20090149464A1
公开(公告)日：2009-06-11
申请号：US11666220
申请日：2005-11-08
申请人： Nicolas Sergeant , Andre Delacourte , Patricia Melnyk , Luc Buee
发明人： Nicolas Sergeant , Andre Delacourte , Patricia Melnyk , Luc Buee
IPC分类号： A61K31/497 , C07D403/14 , A61K31/496 , A61K31/495 , A61P25/28 , C07D241/04 , C07D403/06
CPC分类号： A61K31/495 , C07D215/12 , C07D219/08 , C07D219/12 , C07D235/30 , C07D239/26 , C07D277/28 , C07D295/027 , C07D295/13 , C07D403/12
摘要： Use of 1,4-bis(3-aminoalkyl)piperazine derivatives as defined in formula I or II for the manufacture of a pharmaceutical composition intended for the treatment of neurodegenerative diseases, related neurodegenerative diseases, developmental diseases or cancer. The instant invention is also directed to some specific 1,4-bis(3-aminoalkyl)piperazine derivatives and pharmaceutical composition including them.
摘要翻译： 式I或II中定义的1,4-双（3-氨基烷基）哌嗪衍生物用于制备旨在治疗神经变性疾病，相关神经变性疾病，发育性疾病或癌症的药物组合物。 本发明还涉及一些特定的1,4-双（3-氨基烷基）哌嗪衍生物和包括它们的药物组合物。
-
6.发明申请Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation 审中-公开预防，治疗和诊断与β-淀粉样蛋白形成和/或聚集相关的疾病公开(公告)号：US20080299111A1
公开(公告)日：2008-12-04
申请号：US12151301
申请日：2008-05-06
申请人： Andre Delacourte , Nicolas Sergeant
发明人： Andre Delacourte , Nicolas Sergeant
IPC分类号： A61K31/395 , G01N33/567 , C07K16/00
CPC分类号： A61K39/0007 , C07K14/4711 , C07K16/18 , G01N33/6896 , G01N2800/2821
摘要： The invention provides compositions and methods for prevention and treatment of diseases associated with β-amyloid formation and/or aggregation. Such methods encompass the induction of an immune response against N-terminal truncated and/or post-translationally modified Aβ peptides. These peptides are further used in compositions and methods for the diagnosis of diseases associated with β-amyloid formation and/or aggregation.
摘要翻译： 本发明提供了用于预防和治疗与β-淀粉样蛋白形成和/或聚集相关的疾病的组合物和方法。 这些方法包括诱导针对N-末端截短和/或翻译后修饰的Aβ肽的免疫应答。 这些肽进一步用于用于诊断与β-淀粉样蛋白形成和/或聚集相关的疾病的组合物和方法中。
-
7.发明申请公开(公告)号：US20060166283A1
公开(公告)日：2006-07-27
申请号：US10526899
申请日：2003-09-08
IPC分类号： G01N33/567 , C12N9/22 , C07K16/40
CPC分类号： C07K16/40 , C12Q1/34 , G01N33/6896 , G01N2800/28
摘要： The invention relates to novel markers of the neurodegenerative process, comprising the α chain of the modified ATP synthase. The invention also relates to methods of detection, diagnosis, antibodies, kits and applications of same.
摘要翻译： 本发明涉及神经变性过程的新标记，其包含修饰的ATP合成酶的α链。 本发明还涉及检测，诊断，抗体，试剂盒及其应用的方法。
-
8.发明申请Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation 审中-公开预防，治疗和诊断与β-淀粉样蛋白形成和/或聚集相关的疾病公开(公告)号：US20050175626A1
公开(公告)日：2005-08-11
申请号：US10625854
申请日：2003-07-23
申请人： Andre Delacourte , Nicolas Sergeant
发明人： Andre Delacourte , Nicolas Sergeant
CPC分类号： A61K39/0007 , C07K14/4711 , C07K16/18 , G01N33/6896 , G01N2800/2821
摘要： The invention provides compositions and methods for prevention and treatment of diseases associated with β-amyloid formation and/or aggregation. Such methods encompass the induction of an immune response against N-terminal truncated and/or post-translationally modified Aβ peptides. These peptides are further used in compositions and methods for the diagnosis of diseases associated with β-amyloid formation and/or aggregation.
摘要翻译： 本发明提供了用于预防和治疗与β-淀粉样蛋白形成和/或聚集相关的疾病的组合物和方法。 这些方法包括诱导针对N-末端截短和/或翻译后修饰的Aβ肽的免疫应答。 这些肽进一步用于用于诊断与β-淀粉样蛋白形成和/或聚集相关的疾病的组合物和方法中。
-
9.发明授权Heterocycle compounds and uses thereof for the prevention or treatment of diseases involving formation of amyloid plaques and/or where a dysfunction of the APP metabolism occurs 有权杂环化合物及其用于预防或治疗涉及淀粉样蛋白斑块形成和/或发生APP代谢功能障碍的疾病公开(公告)号：US08680095B2
公开(公告)日：2014-03-25
申请号：US13515570
申请日：2010-12-16
IPC分类号： A61K31/4709 , A61K31/47 , A61K31/496 , A61K31/5377 , A61P25/28
CPC分类号： C07D215/46 , C07D215/44
摘要： The present invention relates to compounds having the following Formula (I) for use in the prevention and/or the treatment of diseases involving formation of amyloid plaques and/or where a dysfunction of the APP metabolism occurs.
摘要翻译： 本发明涉及具有下列通式（I）的化合物，其用于预防和/或治疗涉及淀粉样蛋白斑块形成的疾病和/或发生APP代谢功能障碍。
-
10.发明申请NEW HETEROCYCLE COMPOUNDS AND USES THEREOF FOR THE PREVENTION OR TREATMENT OF DISEASES INVOLVING FORMATION OF AMYLOID PLAQUES AND/OR WHERE A DYSFUNCTION OF THE APP METABOLISM OCCURS 有权新的杂环化合物及其用于预防或治疗涉及淀粉样蛋白形成和/或APP代谢障碍的疾病的疾病的用途公开(公告)号：US20120283256A1
公开(公告)日：2012-11-08
申请号：US13515570
申请日：2010-12-16
IPC分类号： A61K31/4709 , A61K31/496 , C07D401/12 , A61P25/28 , A61K31/5377 , C07D413/12 , C07D215/46 , A61K31/47 , C07D401/14 , C07D413/14
CPC分类号： C07D215/46 , C07D215/44
摘要： The present invention relates to compounds having the following Formula (I) for use in the prevention and/or the treatment of diseases involving formation of amyloid plaques and/or where a dysfunction of the APP metabolism occurs.
摘要翻译： 本发明涉及具有下列通式（I）的化合物，其用于预防和/或治疗涉及淀粉样蛋白斑块形成的疾病和/或发生APP代谢功能障碍。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.019 秒)
